I-MAB (IMAB) Operating Cash Flow per Share : $-0.92 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Operating Cash Flow per Share?

I-MAB's operating cash flow per share for the six months ended in Dec. 2023 was $0.00. I-MAB's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for I-MAB's Operating Cash Flow per Share or its related term are showing as below:

During the past 7 years, I-MAB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.60% per year. The lowest was -30.00% per year. And the median was -13.20% per year.

IMAB's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

I-MAB Operating Cash Flow per Share Historical Data

The historical data trend for I-MAB's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Operating Cash Flow per Share Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.14

0.97

-2.01

-1.92

-2.20

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial								-1.06	-1.04	-0.92	-	-

Competitive Comparison of I-MAB's Operating Cash Flow per Share

For the Biotechnology subindustry, I-MAB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where I-MAB's Price-to-Operating-Cash-Flow falls into.

I-MAB Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

I-MAB's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-182.761	/	83.228
	=	-2.20

I-MAB's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	0	/	83.269
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.92

I-MAB Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of I-MAB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.